APSR2026-307

Yes
Late-Breaking
Submitted
Oral Presentation
AO03-003
 
 
https://storage.unitedwebnetwork.com/files/1285/1213466-46903-APSR2026-307_439584.pptx
Format: PPTX Only
 
Format: PDF Only
07. COPD
9

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Joan Marie Javillo Baguio * The Chinese University of Hong Kong Department of Paediatrics, Faculty of Medicine Hong Kong Hong Kong The Chinese University of Hong Kong Hong Kong Hub of Obstetric and Paediatric Excellence Hong Kong Hong Kong The Chinese University of Hong Kong Laboratory for Paediatric Respiratory Research, Li Ka Shing Institute of Health Sciences, Faculty of Medicine Hong Kong Hong Kong
Chanin Sillapachaiyaporn - The Chinese University of Hong Kong Li Ka Shing Institute of Health Sciences, Faculty of Medicine Hong Kong Hong Kong The Chinese University of Hong Kong School of Pharmacy, Faculty of Medicine Hong Kong Hong Kong
Shuo Wang - The Chinese University of Hong Kong Department of Paediatrics, Faculty of Medicine Hong Kong Hong Kong The Chinese University of Hong Kong Hong Kong Hub of Obstetric and Paediatric Excellence Hong Kong Hong Kong The Chinese University of Hong Kong Laboratory for Paediatric Respiratory Research, Li Ka Shing Institute of Health Sciences, Faculty of Medicine Hong Kong Hong Kong
Stephan Scheeff - The Chinese University of Hong Kong Li Ka Shing Institute of Health Sciences, Faculty of Medicine Hong Kong Hong Kong The Chinese University of Hong Kong School of Pharmacy, Faculty of Medicine Hong Kong Hong Kong
Josefina Xeque Amada - The Chinese University of Hong Kong Li Ka Shing Institute of Health Sciences, Faculty of Medicine Hong Kong Hong Kong The Chinese University of Hong Kong School of Pharmacy, Faculty of Medicine Hong Kong Hong Kong
Calvin Shing Ng - The Chinese University of Hong Kong Department of Surgery, Faculty of Medicine Hong Kong Hong Kong
Fanny Wai San Ko - The Chinese University of Hong Kong Department of Medicine and Therapeutics, Faculty of Medicine Hong Kong Hong Kong
Billy Wai Lung Ng - The Chinese University of Hong Kong Hong Kong Hub of Obstetric and Paediatric Excellence Hong Kong Hong Kong The Chinese University of Hong Kong Li Ka Shing Institute of Health Sciences, Faculty of Medicine Hong Kong Hong Kong The Chinese University of Hong Kong School of Pharmacy, Faculty of Medicine Hong Kong Hong Kong
Renee Wan Yi Chan - The Chinese University of Hong Kong Department of Paediatrics, Faculty of Medicine Hong Kong Hong Kong The Chinese University of Hong Kong Hong Kong Hub of Obstetric and Paediatric Excellence Hong Kong Hong Kong The Chinese University of Hong Kong Laboratory for Paediatric Respiratory Research, Li Ka Shing Institute of Health Sciences, Faculty of Medicine Hong Kong Hong Kong The Chinese University of Hong Kong S.H. Ho Research Centre for Infectious Disease Hong Kong Hong Kong
 
 
 
 
 
 
Presenting Author Details
Joan Marie Javillo
Baguio
1155254185@link.cuhk.edu.hk
+85266868061
Under 30
 
Original Research
A Novel Approach to Preventing Acute Exacerbations of COPD: Targeting Rhinovirus Infections with Bilobalide Derivatives
Maximum 25 words
Abstract Content
Chronic obstructive pulmonary disease (COPD) affects over 100 million individuals in China and remains a leading cause of global mortality. In Hong Kong, prevalence reaches 12.4-25.9% among those aged ≥60 years. Acute exacerbations (AECOPD) carry in-hospital mortality rates of 2.5-14%, rising to 30% in intensive care units. Up to 70% of exacerbations are infection-triggered, with rhinovirus (RV) detected in up to 60% of cases. COPD airways exhibit epithelial remodelling: goblet and basal cell hyperplasia, impaired ciliation, extracellular matrix (ECM) deposition, epithelial-mesenchymal transition (EMT), and increased ferroptosis susceptibility. Current therapies provide symptomatic relief but do not reverse structural pathology or prevent viral exacerbations. We aimed to establish patient-derived airway organoids (AOs) recapitulating baseline COPD and RV-induced AECOPD and evaluate the bilobalide derivative (BD) in this human-relevant platform.
AOs were generated from nasopharyngeal swabs of GOLD 2 COPD patients and age-matched non-COPD controls. AECOPD was modelled using RV-A16 and RV-C15 infection. Viral replication was quantified by qPCR and viral titration. Transcriptomic (RNA-seq) and proteomic profiling were performed using FDR <0.05 and fold change >2 thresholds. BD (10 µM) was administered therapeutically and evaluated using integrated multi-omics and functional analyses.
COPD organoids demonstrated altered epithelial composition, reduced ciliated cell signatures, and enriched ECM remodelling pathways. RNA-seq revealed upregulation of pro-remodelling and inflammatory genes, with suppression of cilium-associated transcripts, consistent with proteomic signatures. RV replication was significantly enhanced in COPD AOs versus controls. BD selectively reduced RV viral load in COPD organoids to level comparable to those in non-COPD levels whereas viral load remained unchanged in non-COPD cultures. Treatment suppressed ECM, collagen, and inflammatory pathways, partially reversing COPD-associated signatures while reducing ferroptosis susceptibility.
Patient-derived COPD organoids model epithelial remodelling and viral susceptibility. BD demonstrates disease-context-specific antiviral and anti-remodelling effects, supporting its development as a disease-modifying therapeutic for viral-induced COPD exacerbations.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
COPD, Rhinovirus, Airway organoids
maximum 3 keywords and no abbreviations, separated by commas
 
300